Loading...
XNAS
QDEL
Market cap1.89bUSD
Dec 05, Last price  
27.76USD
1D
-0.22%
1Q
-3.21%
Jan 2017
29.60%
Name

QuidelOrtho Corp

Chart & Performance

D1W1MN
XNAS:QDEL chart
P/E
P/S
0.68
EPS
Div Yield, %
Shrs. gr., 5y
9.28%
Rev. gr., 5y
39.07%
Revenues
2.78b
-7.17%
92,299,000106,015,000118,065,000128,132,000164,282,000113,339,000158,603,000155,741,000175,410,000182,615,000196,129,000191,603,000277,743,000522,285,000534,890,0001,661,668,0001,698,551,0003,266,000,0002,997,800,0002,782,900,000
Net income
-2.05b
L+20,216.83%
-9,259,00021,718,00013,631,00018,848,00032,883,000-11,271,0007,633,0004,993,0007,390,000-7,074,000-6,079,000-13,808,000-8,165,00074,183,00072,921,000810,287,000704,200,000548,700,000-10,100,000-2,052,000,000
CFO
83m
-70.38%
1,222,00020,731,00027,342,00028,941,00072,843,000-10,293,00046,982,00019,633,00025,682,00035,686,00036,309,00011,815,00027,709,000136,345,000134,485,000629,763,000805,869,000885,300,000280,200,00083,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
IPO date
Feb 01, 1991
Employees
7,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122023‑002021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT